Repatha drug class?

What class is Repatha (evolocumab) in?

Repatha belongs to the PCSK9 inhibitor drug class. It is a monoclonal antibody that lowers LDL cholesterol by blocking PCSK9, a protein that normally reduces the liver’s ability to remove LDL from the blood.

How does a PCSK9 inhibitor work compared with statins or ezetimibe?

Unlike statins (which lower cholesterol production and raise LDL receptor activity) and ezetimibe (which reduces cholesterol absorption), Repatha directly targets PCSK9 to increase LDL receptor recycling on liver cells. This can produce substantial additional LDL-C lowering when used alone or with other lipid-lowering therapies.

Where is Repatha used?

Repatha is used to lower LDL cholesterol in people who have conditions such as primary hypercholesterolemia (including familial hypercholesterolemia) or established cardiovascular disease, typically when LDL goals are not met with other therapies.

What do people usually search next about Repatha’s class?

Common follow-up questions include whether PCSK9 inhibitors can be combined with statins, who qualifies for therapy, and how they compare with the other PCSK9 inhibitor on the market (alirocumab).